All analyses
AI analysis

Muller & Phipps (Ceylon) PLC: research report

OvervaluedbearishNov 9, 2026

Evidence points bearish: September still produced a LKR 3 million net loss while equity attributable to owners was negative. The counterpoint is that the business returned to an operating profit.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bearish

  • The September quarter made a LKR 3.0 million net loss, widening by LKR 2.4 million year-on-year despite an operating profit.
  • Equity attributable to owners was negative LKR 165.0 million at September 2026, while total debt was LKR 302.5 million.

Against this. Operating profit improved by LKR 4.1 million to LKR 3.4 million in the September quarter, ending the prior year's operating loss.

Operating margin
2.6%sector 7.8%
from -0.5% a year earlier
Net margin
-2.3%sector 4.4%
from -0.4% a year earlier, revenue -10.5%
Market cap
Rs 1.1B252nd largest
total value of all shares
P/B
Negative book
book Rs -0.58 per share
Dividend yield
0.00%sector 1.73%
trailing twelve months

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Nov 9, 2026. Sector figures are the median of 35 listed companies in the same sector.

Overview

Muller & Phipps distributes pharmaceutical and healthcare products through a nationwide network, including a newer therapeutic-nutrition offering. The September quarter restored an operating profit, but finance costs and other below-operating items left the group loss-making and further reduced the owners' equity deficit.

Price performance

The share closed at LKR 3.80 on 6 November 2026, after gaining 72.7% over three months while the ASPI fell 0.6%. It was at its 52-week high, so the recent move has taken the price to the top of its own annual range rather than merely recovering part of an earlier decline.

Trading activity has risen above its own recent norm, but liquidity remains limited: median daily turnover was LKR 739,388, and a LKR 1 million order is more than everything that trades on a typical day (135% of it). The record since November 2023 includes seven falls of 15% or more, with the deepest 32%, showing that large retreats have occurred despite the current high.

Valuation

Conventional valuation multiples are unavailable because trailing earnings are negative and book value attributable to owners is negative. That means neither P/E nor P/B can describe what the market is paying for in the usual terms, while no dividend is on record in the last two years.

The market-wide valuation measure places MULL in the Overvalued band, scoring 1 of 100 on price against filed earnings, book value and dividends. The company's own historical P/E and P/B comparisons are also unavailable, so the available valuation evidence offers no earnings, asset-value or income support for the LKR 1.1 billion voting-line market value.

News and sentiment

Direct coverage is thin: the 90-day record contains two material articles, both neutral. Both were reported on 12 October 2026 and concern regulatory disclosures, including a share purchase disclosure; the supplied coverage gives no transaction terms or operating implication.

Financials

September revenue fell 10.5% year-on-year to LKR 132.1 million, but operating profit improved by LKR 4.1 million to LKR 3.4 million. The business therefore covered its direct operating costs in the quarter, unlike a year earlier, but this did not yet translate into profit available to shareholders.

Gross margin was 18.6% versus 20.7% a year earlier, operating margin was 2.5% versus -0.5%, and net margin was -2.3% versus -0.4%. The group still lost about 2 cents on each rupee of sales, and the September net margin was among its worst, ranking sixth out of seven comparable September quarters; gross margin carried the same rank. Operating margin was middling at fourth out of seven.

Below-operating charges were LKR 6.4 million, exceeding operating profit and turning it into a LKR 3.0 million net loss. That loss was LKR 2.4 million wider than the prior-year quarter. The latest audited year, ended March 2026, recorded a LKR 71.4 million net loss, following an LKR 83.7 million loss in the preceding year.

Risks

The central risk is the weak capital position. Equity attributable to owners was negative LKR 165.0 million at September 2026 while total debt was LKR 302.5 million, leaving lenders and creditors materially more important to the financing structure than ordinary shareholders' book capital.

Finance costs and other below-operating charges were LKR 6.4 million in the latest quarter, more than the LKR 3.4 million operating profit. In the year ended March 2026, interest cover was negative 2.96 times, meaning operating profit was insufficient to cover the interest bill.

As at 9 November 2026, the wider backdrop included October inflation of 8.3%, a 100-basis-point policy-rate increase and a 6.7% rupee depreciation through 6 November. As an importer and distributor with material debt, the company is exposed to a more difficult cost and financing environment, although the supplied data does not quantify its currency exposure.

Outlook

As at 9 November 2026, the next decisive event is the December 2026 interim filing, expected between 2 and 14 February 2027. It will show whether the September operating profit was sufficient to absorb finance costs and narrow the net loss, or whether the balance-sheet deficit continues to deepen.

The current data cannot establish whether the operating improvement is durable. It also cannot measure the profit contribution from the newer therapeutic-nutrition distribution activity.

About this report. Generated on Nov 9, 2026 from market data up to Nov 6, 2026, 2 material news articles over 90 days and financials to Sep 30, 2026, and scored 1 of 100 on value (overvalued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports